Though the failure of Regeneron Pharmaceuticals Inc.’s phase II combo trial in wet age-related macular degeneration (AMD) surprised few (including, maybe, the company itself) in the shifting treatment landscape, phase III data due soon from Ophthotech Corp. with its similar pairing could change the picture yet again.